# OnCo record rayzebio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/rayzebio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "rayzebio" ;
  schema:name "RayzeBio (BMS)"@en ;
  schema:description "RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3."@en ;
  schema:url <https://onco.cc/companies/rayzebio/>, <https://www.rayzebio.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.rayzebio.com> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:drugs <https://onco.cc/drugs/ryz101/> ;
  onco:trials <https://onco.cc/trials/nct06590857/>, <https://onco.cc/trials/nct06726161/> .